142 related articles for article (PubMed ID: 33241730)
21. Novel mechanisms and therapeutic approaches in melanoma: targeting the MAPK pathway.
Grimaldi AM; Simeone E; Festino L; Vanella V; Palla M; Ascierto PA
Discov Med; 2015 Jun; 19(107):455-61. PubMed ID: 26175403
[TBL] [Abstract][Full Text] [Related]
22. Mutant BRAF melanomas--dependence and resistance.
Poulikakos PI; Rosen N
Cancer Cell; 2011 Jan; 19(1):11-5. PubMed ID: 21251612
[TBL] [Abstract][Full Text] [Related]
23. Immune Responses to BRAF-Targeted Therapy in Melanoma: Is Targeted Therapy Immunotherapy?
Kelley MC
Crit Rev Oncog; 2016; 21(1-2):83-91. PubMed ID: 27481005
[TBL] [Abstract][Full Text] [Related]
24. Improved survival with MEK inhibition in BRAF-mutated melanoma.
Flaherty KT; Robert C; Hersey P; Nathan P; Garbe C; Milhem M; Demidov LV; Hassel JC; Rutkowski P; Mohr P; Dummer R; Trefzer U; Larkin JM; Utikal J; Dreno B; Nyakas M; Middleton MR; Becker JC; Casey M; Sherman LJ; Wu FS; Ouellet D; Martin AM; Patel K; Schadendorf D;
N Engl J Med; 2012 Jul; 367(2):107-14. PubMed ID: 22663011
[TBL] [Abstract][Full Text] [Related]
25. [The Role of BRAF/MEK Inhibition in Metastatic Malignant Melanoma - a Case Study].
Kopecký J; Kubeček O
Klin Onkol; 2016; 29(2):133-8. PubMed ID: 27081804
[TBL] [Abstract][Full Text] [Related]
26. Immunomodulatory effects of BRAF and MEK inhibitors: Implications for Melanoma therapy.
Kuske M; Westphal D; Wehner R; Schmitz M; Beissert S; Praetorius C; Meier F
Pharmacol Res; 2018 Oct; 136():151-159. PubMed ID: 30145328
[TBL] [Abstract][Full Text] [Related]
27. Vemurafenib: the road to personalized medicine in melanoma.
Amaria RN; Lewis KD; Jimeno A
Drugs Today (Barc); 2012 Feb; 48(2):109-18. PubMed ID: 22384451
[TBL] [Abstract][Full Text] [Related]
28. Targeted Therapy for Melanoma.
Wong DJ; Ribas A
Cancer Treat Res; 2016; 167():251-62. PubMed ID: 26601866
[TBL] [Abstract][Full Text] [Related]
29. A first-in-human phase I, multicenter, open-label, dose-escalation study of the oral RAF/VEGFR-2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF mutation status.
Izar B; Sharfman W; Hodi FS; Lawrence D; Flaherty KT; Amaravadi R; Kim KB; Puzanov I; Sosman J; Dummer R; Goldinger SM; Lam L; Kakar S; Tang Z; Krieter O; McDermott DF; Atkins MB
Cancer Med; 2017 Aug; 6(8):1904-1914. PubMed ID: 28719152
[TBL] [Abstract][Full Text] [Related]
30. Clinical response to a MEK inhibitor in a patient with metastatic melanoma harboring an RAF1 gene rearrangement detected by cancer gene panel testing.
Nakama K; Ogata D; Nakano E; Tsutsui K; Jinnai S; Namikawa K; Takahashi A; Yamazaki N
J Dermatol; 2021 Jun; 48(6):e256-e257. PubMed ID: 33768587
[No Abstract] [Full Text] [Related]
31. Cellular Mechanisms Underlying Complete Hematological Response of Chronic Myeloid Leukemia to BRAF and MEK1/2 Inhibition in a Patient with Concomitant Metastatic Melanoma.
Andrews MC; Turner N; Boyd J; Roberts AW; Grigg AP; Behren A; Cebon J
Clin Cancer Res; 2015 Dec; 21(23):5222-34. PubMed ID: 26202951
[TBL] [Abstract][Full Text] [Related]
32. Targeted therapy for the adjuvant treatment of stage III BRAF-mutated melanoma.
Long G
Clin Adv Hematol Oncol; 2018 Jan; 16(1):25-27. PubMed ID: 29741501
[No Abstract] [Full Text] [Related]
33. Combination of antibodies directed against different ErbB3 surface epitopes prevents the establishment of resistance to BRAF/MEK inhibitors in melanoma.
Fattore L; Malpicci D; Marra E; Belleudi F; Noto A; De Vitis C; Pisanu ME; Coluccia P; Camerlingo R; Roscilli G; Ribas A; Di Napoli A; Torrisi MR; Aurisicchio L; Ascierto PA; Mancini R; Ciliberto G
Oncotarget; 2015 Sep; 6(28):24823-41. PubMed ID: 26208478
[TBL] [Abstract][Full Text] [Related]
34. Targeting BRAF and MEK inhibitors in melanoma in the metastatic, neoadjuvant and adjuvant setting.
Tétu P; Baroudjian B; Lebbe C
Curr Opin Oncol; 2020 Mar; 32(2):85-90. PubMed ID: 31895121
[TBL] [Abstract][Full Text] [Related]
35. Cytokine Release Syndrome During Sequential Treatment With Immune Checkpoint Inhibitors and Kinase Inhibitors for Metastatic Melanoma.
Dimitriou F; Matter AV; Mangana J; Urosevic-Maiwald M; Micaletto S; Braun RP; French LE; Dummer R
J Immunother; 2019 Jan; 42(1):29-32. PubMed ID: 29939877
[TBL] [Abstract][Full Text] [Related]
36. Frequent brain metastases during treatment with BRAF/MEK inhibitors: A retrospective single institutional study.
Nakamura Y; Ishitsuka Y; Tanaka R; Okiyama N; Watanabe R; Saito A; Furuta J; Fujisawa Y
J Dermatol; 2020 Oct; 47(10):1191-1194. PubMed ID: 32602174
[TBL] [Abstract][Full Text] [Related]
37. The survivorship experience for patients with metastatic melanoma on immune checkpoint and BRAF-MEK inhibitors.
Lai-Kwon J; Khoo C; Lo S; Milne D; Mohamed M; Raleigh J; Smith K; Lisy K; Sandhu S; Jefford M
J Cancer Surviv; 2019 Aug; 13(4):503-511. PubMed ID: 31165342
[TBL] [Abstract][Full Text] [Related]
38. Polyglutamate-based nanoconjugates for image-guided surgery and post-operative melanoma metastases prevention.
Epshtein Y; Blau R; Pisarevsky E; Koshrovski-Michael S; Ben-Shushan D; Pozzi S; Shenbach-Koltin G; Fridrich L; Buzhor M; Krivitsky A; Dey P; Satchi-Fainaro R
Theranostics; 2022; 12(14):6339-6362. PubMed ID: 36168618
[No Abstract] [Full Text] [Related]
39. Targeted therapies for cutaneous melanoma.
Kee D; McArthur G
Hematol Oncol Clin North Am; 2014 Jun; 28(3):491-505. PubMed ID: 24880943
[TBL] [Abstract][Full Text] [Related]
40. Trametinib in metastatic melanoma.
Chopra N; Nathan PD
Expert Rev Anticancer Ther; 2015; 15(7):749-60. PubMed ID: 26107021
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
